Twist Bioscience

Twist Bioscience manufactures synthetic DNA using a proprietary silicon-based platform that miniaturizes chemical DNA synthesis onto a semiconductor chip. Each chip writes over 1,000,000 oligonucleotides up to 500 bases in parallel, reducing chemical usage by 99.8% vs. traditional plate-based synthesis. Products: synthetic genes, gene fragments, oligo pools, DNA libraries, NGS sample preparation tools, and antibody discovery services (Biopharma segment).

• monetization model: one-time product sales of synthetic DNA/RNA, NGS target-enrichment panels, libraries; biopharma services/licensing; no subscription/SaaS. (10-K Item 1; segment/revenue notes; SEC EDGAR CIK 0001581280, 10-K/10-Q accession UNKNOWN)
• revenue mix: Synthetic Biology ~two-thirds, NGS ~one-quarter, Biopharma ~5-6% (latest 10-K segment/revenue note; 10-Q interim updates; accession UNKNOWN).
• who pays: R&D budget owners: pharma/biotech discovery groups, diagnostics/lab-services developers, academic/government labs, synthetic-biology firms.
• margin_value_capture: ~40% GAAP gross margin; operating margin negative; value accrues in proprietary silicon-based DNA synthesis platform/consumables, not SaaS. (10-K MD&A/Risk Factors; URL: sec.gov )

• customer classes: Pharma & Biotech, Diagnostics & Lab Services, Clinical Research Orgs, academic/government research labs. (10-K Item 1 Business/risk factors; SEC EDGAR CIK 0001581280, accession UNKNOWN; URL: sec.gov )

Twist’s FY2024 revenue was $313.0 million, up from $245.1 million in FY2023, a year-over-year increase of approximately 28%.

Twist primarily monetizes through product sales, not subscriptions. Revenue is recognized when control transfers to the customer. The company’s 10-K revenue recognition policy describes obligations for custom and catalog synthetic DNA, oligo pools, NGS panels, and related services.

The 10-K identifies customer classes rather than named accounts:

• Academic institutions and universities
• Government research laboratories
• Pharmaceutical and biotechnology companies
• Diagnostic companies
• Agricultural/industrial biotechnology companies
• NGS service providers and clinical testing laboratories
• CRISPR/gene-editing researchers purchasing screening libraries

FY2025 (ended Sep 30, 2025): $376.6M revenue (+20.3% YoY), gross margin 50.7% (up from 42.6% FY2024, 36.6% FY2023). H1 FY2026: $214.4M (+18.1% YoY). Net loss $(77.7M) FY2025, rapidly narrowing from $(208.7M) in FY2024. Cash + investments: $232M. ~59.8M diluted shares. Market cap: ~$5.5B at $91.55 (Aug 2, 2026). All financials from SEC 10-K (filed Nov 17, 2025) and 10-Q (filed May 4, 2026).

TWST controls the highest-throughput, lowest-cost DNA synthesis platform at commercial scale. Every gene therapy, every CRISPR edit, every antibody campaign starts with synthesized DNA. As healthspan biotech scales from 100s to 10,000s of programs, the demand for DNA synthesis scales linearly with each program's design-build-test cycles. TWST's silicon platform is the picks-and-shovels bottleneck feeding the entire synthetic biology value chain.

• Silicon platform writes >1M oligos per chip (mobile-phone-sized) at up to 500bp — 99.8% less chemical volume per gene vs. plate synthesis (10-K Item 1, p. 3)
• FY2025 revenue $376.6M, gross margin at 50.7% — GM expansion of +810bps YoY, indicating operating leverage as platform scales (10-K, Consolidated Statements of Operations)
• 200+ issued/allowed patents + 250+ pending applications worldwide as of Sep 30, 2025 — broad IP moat around silicon-based DNA synthesis (10-K, p. 91 R&D team description)
• H1 FY2026 revenue $214.4M (+18.1% YoY) — growth decelerating slightly from 20.3% in FY2025, but sequential Q2 at $110.7M (10-Q filed May 4, 2026)
• Repeat customer revenue: 99% in FY2025 — extremely sticky once integrated into workflows (10-K, Management's Discussion)
• Revenue by geography: Americas ~33%, EMEA ~30%, APAC ~7% — still early in international penetration (10-K, Revenue by Geography table)

1. Mix-shift: DSPS $56.6M (47.8% of revenue) growing +39%; NGS $61.8M (52.2%) growing +12% → blended +23%. At these run-rates DSPS overtakes NGS as the majority segment within ~2 quarters, structurally lifting blended growth and gross margin (DSPS carries the silicon-platform economics; NGS is the lower-margin tools book).
2. Revenue-per-gene proxy: $118.4M revenue ÷ ~369,000 genes = ~$321/gene blended (rough proxy — genes are heterogeneous in length/complexity, but the +56% YoY gene-volume growth is direct evidence of silicon-platform throughput scaling).
3. SG&A ratio worsening (the key disconfirming signal): SG&A $80.7M = 68.2% of revenue, up from 66.0% a year ago (+220bps) — SG&A grew +27% YoY, faster than +23% revenue growth.
4. Breakeven bridge: Q3 adj EBITDA $(11.3)M. Q4 revenue guide $123.5M midpoint (+$5.1M sequential). At ~53% incremental GM that adds ~$2.7M gross profit — the remaining ~$8.6M gap to breakeven requires SG&A to flatten. But SG&A has been compounding +$5–6M/quarter. Management's "Q4 adjusted-EBITDA breakeven" therefore hinges on opex discipline not yet demonstrated in the trend.